1. Introduction {#sec1}
===============

Perfluoroalkyl acids (PFAAs) are stable man-made perfluorinated organic molecules that have been utilized since the 1950s in the manufacture of a variety of industrial and commercial products suchas fire fighting foams, fluoropolymers for the automobile and aerospace industry, paper food packaging, stain-resistant coatings for carpet and fabric, cosmetics, insecticides, lubricants, and nonstick coatings for cookware. One such PFAA, perfluorooctane sulfonate (PFOS), was identified nearly a decade ago as a persistent organic pollutant which could also be found in the tissues of wildlife throughout the globe \[[@B1]\]. Since that time, a number of perfluorinated sulfonic and carboxylic acids of varying chain length have been shown to be persistent and ubiquitous environmental contaminants. Some of these compounds are also commonly identified in the tissues of humans and wildlife with the 8-carbon PFAAs, PFOS and perfluorooctanoic acid (PFOA), being the most frequently reported in biomonitoring studies (for reviews, see \[[@B2], [@B3]\]). In recent years, blood levels of PFOS and PFOA have gradually begun to decline in the general population \[[@B4], [@B5]\]. This is due in part to a production phase out of PFOS by its principal U.S. manufacturer as well as a commitment by key manufacturers of perfluorinated chemicals to reduce the product content and emissions of PFOA, and related chemistries, under the EPA 2010/2015 PFOA Stewardship Program (<http://www.epa.gov/oppt/pfoa/pubs/stewardship/index.html>). Nevertheless, certain PFAAs are likely to remain of concern for years to come due to their environmental persistence and long biological-half lives \[[@B6]\].

PFOS and PFOA are associated with toxicity in laboratory animals at blood levels that are approximately 2-3 orders of magnitude above those normally observed in humans. This includes hepatomegaly and liver tumors in rats and mice as well as pancreatic and testicular tumors in rats (for review see \[[@B3]\]). Teratogenic activity has also been observed in rats and mice, however, such findings have been limited to maternally toxic doses of PFOS \[[@B7]\], whereas, both PFOS and PFOA have been shown to alter growth and viability of rodent neonates at lower doses \[[@B3]\]. Recent epidemiologic data suggests that typical exposures to these compounds may alter fetal growth and fertility in humans \[[@B8]--[@B12]\]. These studies, however, lack consistency with regard to either compound activity or measured end point; therefore, alternative explanations for such findings have been suggested \[[@B13]\]. Moreover, a recent study of individuals exposed to PFOA in drinking water at levels that were approximately two orders of magnitude higher than the general population did not show an effect on average birth weight or the incidence of low birth weight infants \[[@B14]\].

The mode of action related to PFAA toxicity in rodents is not fully understood. As a class of chemicals, PFAAs activate peroxisome proliferator-activated receptor alpha (PPAR*α*) \[[@B15]--[@B17]\], and chronic activation of this nuclear receptor is thought to be responsible for the liver enlargement and hepatic tumor induction found in laboratory animals \[[@B18]\]. However, activation of PPAR*α* is not thought to be a relevant mode of action for hepatic tumor formation in humans \[[@B19]--[@B24]\], although this assumption has been challenged recently \[[@B25]\]. This does not, however, rule out the possibility that certain PFAAs could have an adverse effect on development since activation of PPAR*α* has been shown to play a role in PFOA-induced neonatal loss in mice \[[@B26]\]. In addition, PPAR*α*-independent modes of action are also likely for various PFAAs. Unlike prototypical activators of PPAR*α*, such as, the fibrate class of pharmaceuticals, PFOA can induce fatty liver in wild-type mice \[[@B27]\]. PFOA can also induce hepatomegaly in PPAR*α*-null mice \[[@B26], [@B28], [@B29]\] and is capable of activating the constitutive androstane receptor (CAR) \[[@B30]--[@B32]\]. Moreover, PFOS can induce neonatal toxicity in the PPAR*α*-null mouse \[[@B33]\].

In the current study, we used global gene expression profiling to assess the transcriptional changes induced by PFOS in the liver of wild-type and PPAR*α*-null mice. The data were compared to results previously published by our group for PFOA and Wy-14,643, a commonly used agonist of PPAR*α* \[[@B34]\]. Our goal was to identify both PPAR*α*-dependent and independent changes induced by PFOS.

2. Materials and Methods {#sec2}
========================

2.1. Animals and Dosing {#sec2.1}
-----------------------

Studies were approved by the U.S. EPA ORD/NHEERL Institutional Animal Care and Use Committee. The facilities and procedures used followed the recommendations of the 1996 NRC "Guide for the Care and Use of Laboratory Animals," the Animal Welfare Act, and the Public Health Service Policy on the Humane Care and Use of Laboratory Animals.

PPAR*α*-null (Null) mice (129S4/SvJae-*P* *p* *a* *r* *a* ^tm1Gonz^/J, stock no. 003580) and wild-type (WT) mice (129S1/SvlmJ, stock no. 002448) were initially purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained as an inbred colony on the 129/Sv background at the U.S. EPA, Research Triangle Park, NC. Animals were housed 5 per cage and allowed to acclimate for a period of one week prior to the conduct of the study. Food (LabDiet 5P00 Prolab RHM3000, PMI Nutrition International, St. Louis, MO) and municipal tap water were provided *ad libitum*. Animal facilities were controlled for temperature (20--24°C), relative humidity (40%--60%), and kept under a 12 hr light-dark cycle. The experimental design matched that of our previous study \[[@B34]\]. PPAR*α*-null and wild-type male mice at 6--9 months of age were dosed by gavage for 7 consecutive days with either 0, 3, or 10 mg/kg PFOS (potassium salt, catalog no. 77282, Sigma Aldrich, St, Louis, MO) in 0.5% Tween 20. Five biological replicates consisting of individual animals were included in each dose group. Dose levels were based on unpublished data from our laboratory and reflect exposures that produce hepatomegaly in adult mice without inducing overt toxicity. Animals utilized for RT-PCR analysis were taken from a separate set of WT and Null mice. PCR dose groups consisted of 4 animals per group and were treated for seven-days with either 10 mg/kg/day PFOS, 3 mg/kg/day PFOA (ammonium salt, catalog no. 77262, Sigma-Aldrich) in 0.5% Tween 20, or 50 mg/kg/day Wy-14,643 (catalog no. C7081, Sigma-Aldrich) in 0.5% methylcellulose, along with vehicle controls. All dosing solutions were freshly prepared each day. At the end of the dosing period, animals were euthanized by CO~2~ asphyxiation and tissue collected from the left lobe of the liver for preparation of total RNA. Tissue prepared for histology was collected from the same group of animals used for microarray analysis and was taken from a section adjacent to that utilized for RNA preparation.

2.2. RNA Preparation {#sec2.2}
--------------------

Collected tissue (≤50 mg) was immediately placed in 1 mL RNA*later* (Applied Biosystems/Ambion, Austin, TX) and stored at −20°C. RNA preparations for microarray analysis were then completed by homogenizing the tissue in 1 mL TRI reagent (Sigma Chemical) followed by processing through isopropanol precipitation according to the manufacturer\'s instructions. The resulting pellets were washed with 80% ethanol and resuspended in RNase free water (Applied Biosystems/Ambion). Preparations were further purified by passing approximately 100 *μ*g per sample through RNeasy spin columns (Qiagen, Valencia, CA). RNA for PCR analysis was prepared using the *mir*VANA miRNA isolation kit (Applied Biosystems/Ambion) according to the manufacturer\'s protocol without further enrichment for small RNAs. All samples used in the study were quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and quality evaluated using a 2100 Bioanalyzer (Agilent, Palo Alto, CA). Only samples with an RNA Integrity number of at least 8.0 (2100 Expert software, version B.01.03) were included in the study \[[@B35]\].

2.3. Histological Examination of Tissue {#sec2.3}
---------------------------------------

Following overnight fixation in Bouins fixative, collected tissue was washed three times in PBS, dehydrated to 70% ethanol, and stored at 4°C until use. On the day of embedding, the tissue was dehydrated through an ethanol gradient to 100% ethanol and paraffin embedded using standard techniques. Five micron sections were then prepared using a rotary microtome prior to routine staining with hematoxylin and eosin.

2.4. Gene Profiling {#sec2.4}
-------------------

Microarray analysis was conducted at the U.S. EPA NHEERL Toxicogenomics Core Facility using Affymetrix GeneChip 430_2 mouse genome arrays according to the protocols recommended by the manufacturer (Affymetrix, Santa Clara, CA). Biotin-labeled cRNA was produced from 5 ug total RNA using Enzo Single-Round RNA Amplification and Biotin Labeling System (Cat. no. 42420-10, Enzo Life Sciences Inc, Farmingdale, NY), quantified using an ND-1000 spectrophotometer, and evaluated on a 2100 Bioanalyzer after fragmentation. To minimize technical day to day variation, labeling and hybridization for all samples were conducted as a single block. Following overnight hybridization at 45°C in an Affymetrix Model 640 GeneChip hybridization oven, the arrays were washed and stained using an Affymetrix 450 fluidics station and scanned on an Affymetrix Model 3000 scanner. Raw data (Affymetrix Cel files) were obtained using Affymetrix GeneChip Operating Software (version 1.4). This software also provided summary reports by which array QA metrics were evaluated including average background, average signal, and 3′/5′ expression ratios for spike-in controls, *β*-actin, and GAPDH. Only arrays of high quality based on low background levels as well as expected 3′/5′ expression ratios for the spike-in controls, *β*-actin, and GAPDH were included in the study. Data are available through the Gene Expression Omnibus at the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/geo>) as accession numbers GSE22871.

2.5. PCR Confirmation of Results {#sec2.5}
--------------------------------

Real-time PCR analysis of selected genes was conducted using 2 micrograms of total RNA. All samples were initially digested using 2 units DNaseI (no. M6101, Promega Corporation, Madison, WI) for 30 min at 37°C followed by 10 min at 65°C in a buffer containing 40 mM Tris (pH 8.0), 10 mM MgSO~4~, and 1 mM CaCl~2~. The RNA was then quantified using a Quant-iT RiboGreen RNA assay kit according to the manufacturer\'s protocol (no.R11490, Invitrogen Corporation, Carlsbad, CA) and approximately 1.5 ug RNA reverse transcribed using a High Capacity cDNA Archive Kit according to the provided protocol (no. 4322171, Applied Biosystems, Foster City, CA). Amplification was performed on an Applied Biosystems model 7900HT Fast Real-Time PCR System in duplicate using 25 ng cDNA and TaqMan Universal PCR Master Mix (no.4304437, Applied Biosystems) in a total volume of 12 *μ*L according to the protocol supplied by the manufacturer. Glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*, Entrez no. 14433), which was uniformly expressed among all samples (cycle threshold deviation less than 0.35), was used as an endogenous reference gene. The following TaqMan assays (Applied Biosystems) were included in the study: *Gapdh* (no. Mm99999915_g1), *Srebf2* (no. Mm01306293_m1), *P* *p* *a* *r* *g* *c*1*a* (Mm0047183_m1), *Nfe2l2 (Mm00477784_m1), Ndufa5* (Mm00471676), *Lss* (no. Mm00461312_m1), *Cyp4a14* (no. Mm00484132_m1), *Cyp7a1* (no. Mm00484152_m1), and *Cyp2b10* (no. Mm00456591_m1). Fold change was calculated using the 2^-ΔΔC^T method of Livak and Schmittgen \[[@B36]\].

2.6. Data Analysis {#sec2.6}
------------------

Body and liver weight data were analyzed by strain using a one-way ANOVA. Individual treatment contrasts were assessed using a Tukey Kramer HSD test (*P* ≤ .05) (JMP 7.0 (SAS, Cary, NC). Microarray data were summarized, background adjusted, and quantile normalized using Robust Multichip Average methodology (RMA Express, ver. 1.0). Prior to statistical analysis, microarray data were filtered to remove probe sets with weak or no signal. Data were analyzed for each strain using a one-way ANOVA across dose (Proc GLM, SAS ver. 9.1, Cary, NC). Individual treatment contrasts were evaluated using a pairwise *t*-test of the least square means. Significant probe sets (*P* ≤ .0025) were evaluated for relevance to biological pathway and function using Ingenuity Pathway Analysis software (<http://analysis.ingenuity.com/>) and DAVID functional annotation software \[[@B37]\]. Duplicate probe sets were resolved using minimum *P*-value. Data were further evaluated without statistical filtering using Gene Set Enrichment Analysis (GSEA) software available from the Broad Institute \[[@B38]\]. Hierarchical clustering and heat maps were generated using Eisen Lab Cluster and Treeview software (version 2.11).

3. Results {#sec3}
==========

3.1. Necropsy and Histopathology {#sec3.1}
--------------------------------

Liver weight increased at the highest dose of PFOS in both WT and Null animals ([Table 1](#tab1){ref-type="table"}). Histological changes were also noted. Vacuole formation was observed in tissue sections from treated WT mice, as well as in sections from control and treated Null mice ([Figure 1](#fig1){ref-type="fig"}). The origin of these vacuoles was not fully apparent. Kudo and Kawashima \[[@B27]\] reported that chronic exposure to PFOA can induce fatty liver in mice due to altered triglyceride transport; hence, vacuolization in the current study may be the result of similar changes in WT mice. In Null mice, vacuole formation may also reflect increased triglyceride retention due to reduced hepatic fatty acid catabolism. Furthermore, our group has suggested that a certain degree of vacuolization may be unrelated to triglyceride retention in PFOA-exposed Null mice \[[@B28]\]. It is possible therefore, that hepatic vacuolization might be associated with the liver weight increase observed in treated Null animals.

3.2. Gene Profiling {#sec3.2}
-------------------

Based on the number of genes significantly altered by PFOS (*P* ≤ .0025), gene expression changes in WT mice were more evident at the higher dose of PFOS compared to the lower dose. This was in contrast to changes observed in Null mice where the number of transcripts influenced by PFOS was similar across either dose group. Hence, certain PPAR*α*-independent effects were found to be robust in Null mice even at the lowest dose of PFOS. This pattern of gene expression also varied from that previously observed by our group for PFOA where only moderate changes were found in Null mice compared to WT animals \[[@B34]\] ([Table 2](#tab2){ref-type="table"}). By examining the expression of a small group of well characterized markers of PPAR*α* transactivation, PFOS also appeared to be a less robust activator of murine PPAR*α* than PFOA ([Figure 2](#fig2){ref-type="fig"}), a conclusion formerly reported by others \[[@B17], [@B39], [@B40]\].

In WT mice, PFOS modified the expression of genes related to a variety of PPAR*α*-regulated functions including lipid metabolism, peroxisome biogenesis, proteasome activation, and the inflammatory response. Genes affected in both WT and Null mice consisted of transcripts related to lipid metabolism, inflammation, and xenobiotic metabolism, including the CAR inducible gene, *Cyp2b10*. It should be stressed, however, that those changes associated with the inflammatory response in Null mice were modest and were only apparent within the context of similar but more robust changes in WT mice. Several categories of genes were also uniquely regulated in Null mice by PFOS including up-regulation of genes in the cholesterol biosynthesis pathway, along with modest down-regulation of genes (\<1.5 fold change) associated with oxidative phosphorylation and ribosome biogenesis ([Figure 3](#fig3){ref-type="fig"}). Changes related to ribosome biogenesis were particularly subtle and were identified by the computational method provided by GSEA using the complete set of expressed genes without statistical filtering. This approach allowed for an a priori set of genes to be evaluated for significant enrichment without regard for the statistical significance of individual genes. Among the changes uniquely induced by PFOS in Null mice was up-regulation of *Cyp7a1*, an important gene related to bile acid/cholesterol homeostasis. Data for individual genes are provided in Tables [3](#tab3){ref-type="table"}--[10](#tab10){ref-type="table"}.

3.3. PCR Confirmation {#sec3.3}
---------------------

The results from real-time RT-PCR analysis of selected genes are summarized, along with the corresponding results from the microarray analysis, in [Figure 4](#fig4){ref-type="fig"}. The data from both assays were in close agreement. It should be pointed out that while up-regulation of *Cyp2b10* was confirmed in treated WT and Null mice, it remained a low copy number transcript in these animals. Down-regulation of *Ndufa5*, a gene which encodes for a subunit of mitochondrial respiratory chain complex I, could not be confirmed in treated Null mice. This result, however, was not surprising because the changes associated with oxidative phosphorylation in the current study were small and, therefore, difficult to detect given the technical variation normally associated with real-time PCR. As predicted based on the microarray results, PFOS did not appear to up-regulate the expression of *Srebf2*, *P* *p* *a* *r* *g* *c*1*a*, or *Nfe2l2* (*Nrf2*) in either WT or Null mice.

4. Discussion {#sec4}
=============

In the current study, exposure to PFOS induced both PPAR*α*-dependent and PPAR*α*-independent effects in the murine liver. In WT mice, the observed changes were primarily indicative of a weak PPAR*α* activator. As such, PFOS induced hepatomegaly and altered the expression of genes related to a number of biological functions known to be regulated by PPAR*α* including lipid metabolism, peroxisome biogenesis, proteasome activation, and the inflammatory response \[[@B41]--[@B45]\]. These data are also in agreement with previous studies done in either the adult or fetal rodent \[[@B46]--[@B50]\]. Among those effects found to be independent of PPAR*α* was altered expression of genes associated with xenobiotic metabolism, including up-regulation of the CAR inducible gene, *Cyp2b10*. Such changes, which were found in both WT and Null mice, were also consistent with results previously reported by our group for PFOA \[[@B31], [@B32]\]. Although xenobiotic metabolism can be regulated by more than one nuclear receptor \[[@B51]\], the ability of PFOA or perfluorodecanoic acid (PFDA) to activate CAR has been demonstrated in experiments using multiple receptor-null mouse models \[[@B30]\]; therefore, it is likely that PFOS functions as an activator of CAR as well. Additional PPAR*α*-unrelated effects were further indicated by regulation of a group of genes associated with lipid metabolism and inflammation in both WT and Null mice. As suggested for mice exposed to PFOA \[[@B34], [@B32]\], such changes could be due to activation of either PPAR*γ* and/or PPAR*β*/*δ*. Indeed, studies done using transient transfection reporter cell assays indicate that PFOS and PFOA have the potential to modestly activate other PPAR isotypes. \[[@B39], [@B40]\]. Furthermore, peroxisome proliferation, a hallmark of PPAR*α* transactivation, can also be induced in the rodent liver by activating PPAR*γ* and/or PPAR*β*/*δ* \[[@B52]\]; hence, a degree of functional overlap might be expected among the PPAR isotypes. Particularly noteworthy were PPAR*α*-independent effects that were unique to Null mice since they were not previously observed in mice treated with PFOA \[[@B34], [@B32]\]. These included modified expression of genes associated with ribosome biogenesis, oxidative phosphorylation, and cholesterol biosynthesis. While activation of PPAR*α* has been linked to changes in cholesterol homeostasis \[[@B18]\] and oxidative phosphorylation \[[@B53]\], it should be stressed that such changes were not simply the result of targeted disruption of PPAR*α* because they were observed in treated animals over and above those effects which occurred in Null controls. Moreover, in the current study, genes linked to cholesterol biosynthesis were found to be up-regulated in Null mice, an effect that mirrored changes previously reported in WT mice treated with the PPAR*α* agonist, Wy 14,643 \[[@B34]\].

Recognition that PPAR ligands can induce "off-target" effects is not new (for review, see \[[@B54]\]). It is not clear, however, whether the effects described for Null mice in the current study were the result of modified activity of transcription regulators, which only became apparent in the absence of PPAR*α* signaling, or whether these changes represent some other aspect of murine metabolism affected by PFOS. Of interest was up-regulation of *Cyp7a1*. This gene encodes for an enzyme responsible for the rate limiting step in the classical pathway of hepatic bile acid biosynthesis and is important for bile acid/cholesterol homeostasis \[[@B55]\]. While targeted disruption of PPAR*α* does not appear to alter basal levels of *Cyp7a1* \[[@B56]\], PPAR*α* agonists such as, fibrates can reduce both *Cyp7a1* gene expression and bile acid biosynthesis in wild-type rodents \[[@B57]\] possibly by interfering with promoter binding of HNF4 \[[@B58]\]. Regulation of *Cyp7a1* is often associated with the liver X receptor (LXR) \[[@B59]\] but it is tightly controlled by multiple pathways and may be positively regulated by the pregnane X receptor (PXR) \[[@B60]\] and the retinoid X receptor (RXR) as well \[[@B61]\]. While the two LXR subtypes, LXR*α* and LXR*β*, are lipogenic and play a key role in regulating cholesterol homeostasis \[[@B62], [@B63]\], they are not thought to be positive regulators of genes in the cholesterol biosynthesis pathway \[[@B64]\].

Additional signaling pathways that may contribute to the effects observed in Null mice include pathways regulated by Srebf2 (Srebp2) and PPARGC1*α* (PGC-1*α*). Srebf2 is one member of a group of membrane-bound transcription factors that play an important role in maintaining lipid homeostasis. SREBF2 is best known for positively regulating cholesterol synthesis in the liver and other tissues (Horton et al., 1998). While decreased nuclear abundance of SREBP2 has been linked to increased hepatic PPAR*α* activity in rats \[[@B65]\], a PPAR*α*-independent mechanism of action has been suggested in mice as well which, in combination with increased expression of CYP7a1, may paradoxically also function via decreased SREBF2 signaling \[[@B66]\]. It should be noted that transcript levels of *Srebf2* were not affected in the current study nor was PFOS found to alter *Srebf2* expression in cultured chicken hepatocytes \[[@B67]\], although such changes are not necessarily required for transcription factor regulation. Rather than functioning as a transcription factor like SREBP2, PPARGC-1*α* is a transcription coactivator that was first described as a moderator of PPAR*γ*-induced adaptive thermogenesis in brown adipose tissue \[[@B68]\]. PPARGC-1*α* is now known to regulate various aspects of energy metabolism in different tissues by interacting with a host of transcription factors, including PPAR*α* \[[@B69], [@B70]\]. Certain PPAR ligands have been shown to inhibit oxidative phosphorylation \[[@B71]--[@B74]\] and Walters et al. \[[@B75]\] recently reported that high doses of PFOA could modify mitochondrial function in rats via a pathway involving PPARGC-1*α*. Unlike their results, however, PFOS did not induce a change in expression of *Ppargc*-1*α* or its downstream target, *Nrf2*, in the current study. Cellular regulation of metabolism, however, is complex and there are a number of potentially interrelated signaling pathways, including HNF4*α* \[[@B76]\] and TOR \[[@B77]\], that based on their biological function could theoretically be linked to the effects observed in PFOS-treated Null mice. Given the diversity of effects observed in the current study, it is likely that more than one signaling pathway is responsible for the biological activity reported for PFOS.

Because certain effects were found only in Null mice, their relevance to the toxicity of PFOS is not clear. Although the developmental toxicity of PFOS has been shown to be independent of PPAR*α* in murine neonates \[[@B33]\], it has also been suggested that rather than causing primary alterations to the murine transcriptome, PFOS may alter the physicochemical properties of fetal lung surfactant as the critical event related to toxicity in these animals \[[@B78]--[@B80]\]. It should also be stressed that in Null animals the magnitude of change found for certain effects was small, hence, the reported effects in the current study were subtle. On the other hand, these data serve to reinforce two recurring themes regarding the biological activity of PFAAs. First, as a class of compounds, the activity of PFAAs may be quite variable. Differences exist among PFAAs with regard to chain length and functional group which influence, not only the elimination half-life of assorted PFAAs \[[@B3], [@B6]\] and their ability to activate PPAR*α* \[[@B17]\], but potentially their ability to modify the function of other transcription regulators as well. Second, the biological activity of PFAAs is likely to differ from that observed for fibrate pharmaceuticals, the most commonly studied ligands of PPAR*α*. While much has been learned from studies using fibrate-exposed PPAR*α*-null and PPAR*α*-humanized mice regarding the relevance of chronic PPAR*α* activation to liver tumor formation in humans \[[@B21]\], additional information concerning the biological activity of specific PFAAs remains relevant for risk assessment.

In summary, PFOS is a PPAR*α* agonist that is capable of inducing a variety of PPAR*α*-independent effects in WT and Null mice, although the toxicological relevance of these changes is uncertain. A number of these effects such as, altered expression of genes involved in lipid metabolism, inflammation, and xenobiotic metabolism were observed in both WT and Null animals, and were consistent with prior studies done with either PFOS or PFOA. Other effects involving genes associated with ribosome biogenesis, oxidative phosphorylation, and cholesterol biosynthesis were unique to Null mice and may represent targeted signaling pathways not yet described for certain PFAAs.

The authors would like to thank Dr. Hongzu Ren for conducting the microarray analysis and Drs. Jennifer Seed and Neil Chernoff for their critical review of this manuscript.

![Hematoxylin-and eosin-stained tissue sections from control and PFOS treated mice. Control WT and Null mice are shown in panels (a) and (b), respectively. WT and null mice treated with 10 mg/kg/day PFOS are shown in panels (c) and (d), respectively. Vacuole formation was observed in sections from treated WT mice, and in sections from control and treated Null mice. Mice exposed to 3 mg/kg/day PFOS were similar to controls (data not shown). Bar = 50 *μ*m.](PPAR2010-794739.001){#fig1}

![Expression of a group of well characterized markers of PPAR*α* transactivation in WT and Null mice. The response to PFOS in WT mice was less robust than that previously observed for either PFOA or Wy14,643. Red or green correspond to average up- or down- regulation, respectively.](PPAR2010-794739.002){#fig2}

![Functional categories of genes modified by PFOS in WT and Null mice. In WT mice, PFOS altered the expression of genes related to a variety of PPAR*α*-regulated functions including lipid metabolism, peroxisome biogenesis, proteasome activation, and the inflammatory response. Genes affected in both WT and Null mice consisted of transcripts related to lipid metabolism, inflammation, and xenobiotic metabolism. Several categories of genes were uniquely regulated by PFOS in Null mice including up-regulation of genes in the cholesterol biosynthesis pathway as well as modest down-regulation of genes associated with oxidative phosphorylation and ribosome biogenesis. Red or green corresponds to average up- or down- regulation, respectively.](PPAR2010-794739.003){#fig3}

![Microarray and Real-time PCR analysis of selected genes. Data from both assays were in close agreement. Small changes in *Ndufa5*expression, a gene which encodes for a subunit of mitochondrial respiratory chain complex I, could not be confirmed by RT-PCR. As predicted based on microarray analysis, PFOS did not appear to up-regulate the expression of *Srebf2*, *P* *p* *a* *r* *g* *c*1*a* *(Pgc-1a)*, or *Nfe2l2* (*Nrf2*) in WT or Null mice. Red or green correspond to average up- or down- regulation, respectively.](PPAR2010-794739.004){#fig4}

###### 

Average body weight and liver weight of control and PFOS-treated mice on the day of tissue collection.^1^

  Dose group   WT           Null                                                           
  ------------ ------------ --------------- ----------------- ------------ --------------- -----------------
  0 mg/kg      28.3 ± .0    1.21 ± 0.17     0.043 ± 0.014     30.3 ± 1.3   1.04 ± 0.06     0.034 ± 0.003
  3 mg/kg      26.2 ± 1.5   1.12 ± 0.18     0.043 ± 0.002     28.0 ± 1.2   1.20 ± 0.05     0.043 ± 0.001
  10 mg/kg     31.4 ± 1.5   1.98 ± 0.11\*   0.062 ± 0.003\*   30.2 ± 1.7   1.48 ± 0.16\*   0.049 ± 0.012\*

^1^Data are mean ± SE, \*Significantly different than control (*P* ≤ .05).

###### 

Number of fully annotated genes altered by PFOS, PFOA^1^, or Wy-14,643^1^ in wild-type and PPAR*α*-null mice (*P* ≤ .0025)^2^.

                 POS   PFOA   Wy 14,643   
  -------------- ----- ------ ----------- -----
  Wild-type      81    906    879         902
  PPAR*α*-null   630   808    176         10

^1^From Rosen et al. (2008), ^2^ Based on Ingenuity Pathways Analysis database.

###### 

Average fold change for genes related to lipid metabolism in wild-type and PPAR*α*-null male mice following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS.

  ------------------------------------------------------------------------------------------------------------------------
                                                                   WT                                   Null    
  --------- ------------------------------------- -------- ------- -------- ------- ----------- ------- ------- ----------
  ACAA1     acetyl-CoA\                           113868   1.89    2.92     1.61    2.10\*\*    1.22    1.37    1.53\*
            acyltransferase 1                                                                                   

  ACAA1B    acetyl-CoA\                           235674   2.38    2.70     1.49    1.40\*\*    3.00    1.09    1.19\*
            acyltransferase 1B                                                                                  

  ACAD10    acyl-CoA dehydrogenase,\              71985    1.51    2.39     −1.18   1.38\*\*    −1.01   1.05    1.20\*
            member 10                                                                                           

  ACADL     acyl-CoA dehydrogenase,\              11363    3.03    2.86     1.40    1.68\*\*    2.50    1.34    1.59\*\*
            long chain                                                                                          

  ACADM     acyl-CoA dehydrogenase,\              11364    1.70    1.30     1.21    1.31\*\*    1.06    1.11    1.10
            C-4 to C-12                                                                                         

  ACADS     acyl-CoA dehydrogenase,\              66885    1.03    1.52     1.22    1.31\*      −1.13   −1.12   −1.08
            C-2 to C-3                                                                                          

  ACADSB    acyl-CoA dehydrogenase,\              66885    −1.56   −1.64    −1.04   −1.39\*\*   −1.26   1.00    −1.23
            short/branched                                                                                      

  ACADVL    acyl-CoA dehydrogenase,\              11370    1.92    1.80     1.44    1.49\*\*    1.16    1.04    1.12
            very long chain                                                                                     

  ACAT1     acetyl-CoA\                           101446   −1.01   1.10     1.45    1.36\*      −1.55   −1.05   −1.17
            acetyltransferase 1                                                                                 

  ACAT2     acetyl-CoA\                           110460   2.59    1.68     1.14    1.34\*      1.26    1.58    1.69\*\*
            acetyltransferase 2                                                                                 

  ACOT1     acyl-CoA thioesterase 1               26897    19.48   73.06    3.27    6.82\*\*    2.95    1.53    2.02

  ACOT3     acyl-CoA thioesterase 3               171281   2.55    32.83    2.42    6.41\*\*    −1.59   1.46    1.86

  ACOT2     acyl-CoA thioesterase 2               171210   3.83    19.29    1.91    7.32\*\*    1.78    1.25    1.52

  ACOX1     acyl-CoA oxidase 1                    11430    5.65    7.17     1.23    1.49\*\*    1.51    1.30    1.29\*\*

  ACSL1     acyl-CoA synthetase long-\            14081    1.34    2.36     1.28    1.36\*\*    1.01    1.31    1.30
            chain member1                                                                                       

  ACSL3     acyl-CoA synthetase long-\            74205    2.25    1.90     1.28    1.69\*\*    1.11    1.77    1.63
            chain member3                                                                                       

  ACSL4     acyl-CoA synthetase long-\            50790    1.95    2.00     1.03    1.42\*      1.51    1.34    1.29
            chain member4                                                                                       

  ACSL5     acyl-CoA synthetase long-\            433256   3.06    2.76     1.24    1.31\*\*    1.38    1.23    1.28
            chain member5                                                                                       

  ALDH1A1   aldehyde dehydrogenase 1,\            11668    1.56    1.59     1.07    1.12\*\*    1.22    1.16    1.17
            member A1                                                                                           

  ALDH1A7   aldehyde dehydrogenase 1, A7          26358    1.83    1.86     1.12    1.24\*      1.55    1.26    1.35

  ALDH3A2   aldehyde dehydrogenase 3,\            11671    3.65    7.72     2.10    3.80\*\*    2.30    1.73    2.20\*\*
            member A2                                                                                           

  ALDH9A1   aldehyde dehydrogenase 9,\            56752    1.80    1.91     1.27    1.50\*\*    1.21    1.05    1.11\*
            member A1                                                                                           

  CPT1B     carnitine palmitoyltransferase\       12896    2.29    1.50     1.23    2.69\*\*    −1.00   1.13    1.11
            1B (muscle)                                                                                         

  CPT2      carnitine palmitoyltransferase II     12896    1.33    2.54     1.58    2.03\*\*    1.44    1.15    1.34

  CYP4A14   cytochrome P450, 4, a,\               13119    75.38   103.48   11.26   12.28\*\*   12.75   −1.09   2.22
            polypeptide 14                                                                                      

  DCI       dodecenoyl-CoA\                       13177    2.91    4.55     1.90    2.38\*\*    1.99    1.04    1.38\*
            delta isomerase                                                                                     

  ECH1      enoyl CoA hydratase 1,\               51798    3.27    5.23     1.93    2.49\*\*    2.10    1.16    1.39
            peroxisomal                                                                                         

  EHHADH    enoyl-CoA, hydratase                  74147    27.89   22.11    2.37    4.34\*\*    1.37    1.32    1.52\*

  FABP1     fatty acid binding protein 1, liver   14080    −1.27   1.02     1.11    1.24\*\*    1.25    −1.09   −1.23

  HADHA     Trifunctional protein, alpha unit     97212    2.13    2.95     1.37    1.65\*\*    1.01    1.06    1.02

  HADHB     Trifunctional protein, beta unit      231086   2.33    3.43     1.37    1.60\*\*    1.08    −1.15   −1.28\*

  HSD17B4   hydroxysteroid (17-beta)\             15488    2.03    2.56     1.34    1.45\*\*    −1.13   1.12    1.20\*
            dehydrogenase4                                                                                      

  SLC27A1   solute carrier 27, member 1           26457    9.14    8.22     −1.02   1.14\*      −1.57   1.04    1.04

  SLC27A2   solute carrier 27,\                   26458    1.48    1.80     1.19    1.16\*\*    1.33    1.10    1.05
            member 2                                                                                            

  SLC27A4   solute carrier 27,\                   26569    1.87    1.91     1.04    1.31\*\*    −1.03   1.09    1.07
            member 4                                                                                            
  ------------------------------------------------------------------------------------------------------------------------

^1^From Rosen et al. (2008),

\*Significantly different than control (*P* ≤ .03),

\*\*Significantly different than control (*P* ≤ .0025)

###### 

Average fold change for genes related to proteasome biogenesis in wild-type and PPAR*α*-null male mice following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS.

  --------------------------------------------------------------------------------------------------------
                                                            WT                         Null    
  -------- ----------------------- -------- ------- ------- ------- ---------- ------- ------- -----------
  PSMA1    proteasome unit,\       26440    1.61    1.38    1.15    1.31\*     1.17    −1.29   −1.34
           alpha type, 1                                                                       

  PSMA2    proteasome unit,\       19166    −1.46   −1.15   1.09    1.23\*\*   −1.34   −1.20   −1.07
           alpha type, 2                                                                       

  PSMA3    proteasome unit,\       19167    1.33    1.22    1.12    1.14       1.28    −1.13   −1.17
           alpha type, 3                                                                       

  PSMA4    proteasome unit,\       26441    1.19    1.32    1.10    1.19\*     1.01    −1.04   1.05
           alpha type, 4                                                                       

  PSMA5    proteasome unit,\       26442    1.67    1.59    1.12    1.26\*\*   1.15    −1.12   1.09
           alpha type, 5                                                                       

  PSMA6    proteasome unit,\       26443    1.20    1.29    1.14    1.24\*\*   1.06    −1.14   −1.06
           alpha type, 6                                                                       

  PSMA7    proteasome unit,\       26444    1.47    1.60    1.23    1.53\*\*   1.23    −1.12   1.11
           alpha type, 7                                                                       

  PSMB1    proteasome unit,\       19170    1.09    1.29    1.07    1.28\*     1.04    −1.17   1.13\*
           beta type, 1                                                                        

  PSMB10   proteasome unit,\       19171    −1.42   −1.48   −1.25   −1.19      −1.57   −1.14   −1.21\*\*
           beta type, 10                                                                       

  PSMB2    proteasome unit,\       26445    1.33    1.48    1.05    1.31\*\*   1.02    −1.20   1.05
           beta type, 2                                                                        

  PSMB3    proteasome unit,\       26446    1.22    1.47    1.21    1.36\*\*   1.04    −1.37   −1.20
           beta type, 3                                                                        

  PSMB4    proteasome unit,\       19172    1.59    1.65    1.27    1.55\*\*   1.22    −1.12   1.09
           beta type, 4                                                                        

  PSMB5    proteasome unit,\       19173    1.34    1.74    1.04    1.24\*\*   1.02    −1.15   1.03
           beta type, 5                                                                        

  PSMB6    proteasome unit,\       19175    1.54    1.83    1.08    1.24\*     1.19    −1.23   −1.09
           beta type, 6                                                                        

  PSMB7    proteasome unit,\       19177    1.46    1.33    1.07    1.15\*\*   1.13    −1.17   −1.09
           beta type, 7                                                                        

  PSMB8    proteasome unit,\       16913    −1.61   −2.00   −1.44   −1.51      −1.38   −1.23   −1.45\*\*
           beta type, 8                                                                        

  PSMB9    proteasome unit,\       16912    1.24    −1.12   −1.31   −1.09      −1.10   −1.11   −1.30\*\*
           beta type, 9                                                                        

  PSMC1    proteasome 26S unit,\   19179    1.44    1.00    1.19    1.15\*     1.11    −1.06   1.01
           ATPase, 1                                                                           

  PSMC6    proteasome 26S unit,\   67089    1.18    1.21    1.09    −1.02      1.07    1.14    −1.16
           ATPase, 6                                                                           

  PSMD1    proteasome 26S unit,\   70247    1.20    1.22    1.15    1.25\*\*   1.09    1.03    1.15
           non-ATPase, 1                                                                       

  PSMD11   proteasome 26S unit,\   69077    1.56    1.38    1.09    1.26\*     −1.17   1.16    1.32
           non-ATPase, 11                                                                      

  PSMD12   proteasome 26S unit,\   66997    1.34    1.27    1.10    1.14       1.20    −1.03   1.04
           non-ATPase, 12                                                                      

  PSMD13   proteasome 26S unit,\   23997    1.21    1.38    1.14    1.26\*     −1.03   −1.38   −1.42\*\*
           non-ATPase, 13                                                                      

  PSMD14   proteasome 26S unit,\   59029    −1.39   −1.42   1.17    1.31\*     1.31    1.01    1.17
           non-ATPase, 14                                                                      

  PSMD2    proteasome 26S unit,\   21762    1.34    1.32    1.14    1.24\*     1.10    1.09    1.30\*\*
           non-ATPase, 2                                                                       

  PSMD3    proteasome 26S unit,\   22123    −1.35   −1.19   1.17    1.29\*     1.08    1.04    1.22\*
           non-ATPase, 3                                                                       

  PSMD4    proteasome 26S unit,\   19185    1.31    1.92    1.19    1.38\*\*   1.03    −1.07   1.17\*
           non-ATPase, 4                                                                       

  PSMD6    proteasome 26S unit,\   66413    1.17    1.33    1.10    1.14\*     1.07    −1.06   1.04
           non-ATPase, 6                                                                       

  PSMD7    proteasome 26S unit,\   17463    1.13    1.27    1.13    1.24\*     1.02    −1.19   −1.22\*
           non-ATPase, 7                                                                       

  PSMD8    proteasome 26S unit,\   57296    1.68    1.24    1.03    1.30\*\*   1.16    −1.15   −1.00
           non-ATPase, 8                                                                       

  PSME1    proteasome activator\   19186    1.22    −1.00   −1.05   1.32\*\*   1.27    −1.10   −1.09
           unit 1                                                                              

  VCP      valosin−containing\     269523   1.40    1.49    1.04    1.12       1.07    1.13    1.21\*\*
           protein                                                                             
  --------------------------------------------------------------------------------------------------------

^1^From Rosen et al. (2008),

\*Significantly different than control (*P* ≤ .03),

\*\*Significantly different than control (*P* ≤ .0025).

###### 

Average fold change for genes related to peroxisome biogenesis in wild-type and PPAR*α*-null male mice following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS.

  -----------------------------------------------------------------------------------------------------------
                                                                WT                         Null    
  -------- --------------------------- -------- ------- ------- ------- ---------- ------- ------- ----------
  PECI     peroxisome D3, D2-enoyl-\   23986    1.73    3.15    1.61    1.87\*\*   1.96    1.42    1.57\*\*
           CoA isomerase                                                                           

  PEX1     peroxisomal biogenesis\     71382    1.25    1.84    1.07    1.21\*\*   −1.02   1.10    1.14\*
           factor 1                                                                                

  PEX11A   peroxisomal biogenesis\     18631    1.80    6.71    1.70    2.99\*\*   1.04    −1.09   −1.11
           factor 11 alpha                                                                         

  PEX12    peroxisomal biogenesis\     103737   1.07    1.36    1.11    1.17\*     1.09    1.17    1.30\*
           factor 12                                                                               

  PEX13    peroxisomal biogenesis\     72129    1.04    1.58    1.01    1.09       1.02    1.09    1.16\*
           factor 13                                                                               

  PEX14    peroxisomal biogenesis\     56273    1.06    1.24    1.03    1.25\*     1.03    1.05    1.13
           factor 14                                                                               

  PEX16    peroxisomal biogenesis\     18633    1.51    1.44    1.13    1.33\*\*   −1.00   −1.12   −1.03
           factor 16                                                                               

  PEX19    peroxisomal biogenesis\     19298    1.61    2.25    1.19    1.36\*\*   1.12    1.15    1.32\*\*
           factor 19                                                                               

  PEX26    peroxisomal biogenesis\     74043    −1.32   −1.86   1.01    1.26       1.01    1.29    1.10
           factor 26                                                                               

  PEX3     peroxisomal biogenesis\     56535    1.50    1.77    1.13    1.37\*\*   −1.05   1.09    1.20\*
           factor 3                                                                                

  PEX6     peroxisomal biogenesis\     224824   1.08    −1.06   1.12    1.16       1.30    −1.08   1.09
           factor 6                                                                                

  PXMP2    peroxisomal membrane\       19301    −1.22   −1.29   −1.08   −1.20\*    −1.28   −1.13   −1.06
           protein 2                                                                               

  PXMP4    peroxisomal membrane\       59038    1.62    2.09    1.61    1.62\*     1.99    −1.03   1.01
           protein 4                                                                               
  -----------------------------------------------------------------------------------------------------------

^1^From Rosen et al. \[[@B34]\],

\*Significantly different than control (*P* ≤ .03),

\*\*Significantly different than control (*P* ≤ .0025).

###### 

Average fold change for genes related to the inflammatory response in wild-type and PPAR*α*-null male mice following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS.

  -------------------------------------------------------------------------------------------------------------
                                                                WT                          Null    
  ---------- ------------------------- -------- ------- ------- ------- ----------- ------- ------- -----------
  APCS       amyloid P component,\     20219    −1.50   −2.33   −1.23   −1.28       −1.19   1.41    1.13
             serum                                                                                  

  C1QA       complement component\     12259    −1.75   −1.40   −1.13   −1.17       −1.31   −1.24   −1.34\*\*
             1QA                                                                                    

  C1R        complement component 1r   50909    −2.67   −1.78   −1.15   −1.23\*     −1.22   1.16    −1.17\*

  C1S        complement component 1s   317677   −3.73   −2.53   −1.14   −1.62\*\*   −1.52   1.06    −1.11

  C2         complement component 2    12263    −2.56   −1.91   −1.37   −1.32\*     −1.18   1.10    1.11

  C3         complement component 3    12266    −1.41   −1.41   −1.04   −1.04       −1.22   1.13    1.08\*

  C4B        complement component 4B   12268    −2.35   −2.15   −1.08   −1.28       −1.91   1.15    −1.13

  C4BP       complement component\     12269    −1.86   −1.82   −1.11   −1.19       1.02    1.39    1.13
             4 binding prot                                                                         

  C6         complement component 6    12274    −2.66   −1.27   −1.35   −1.08       1.90    1.12    1.06

  C8A        complement\               230558   −3.62   −1.94   −1.17   −1.31\*     −1.17   1.19    1.04
             component 8, alpha                                                                     

  C8B        complement\               110382   −5.25   −2.99   −1.20   −1.60\*\*   −1.12   1.11    1.02
             component 8, beta                                                                      

  C8G        complement\               69379    −1.59   −1.35   −1.05   −1.17\*     −1.34   −1.10   −1.17\*\*
             component 8, gamma                                                                     

  C9         complement\               12279    −2.12   −2.64   −1.35   −1.58\*\*   −1.46   1.08    −1.19\*
             component 9                                                                            

  CFB        complement\               14962    −1.81   −1.77   −1.07   −1.26       −1.39   1.07    −1.11
             factor B                                                                               

  CFH        complement\               12628    −2.39   −2.30   −1.19   −1.62       −1.76   1.45    −1.35
             factor H                                                                               

  CFI        complement\               12630    −1.63   −1.77   −1.06   −1.15       −1.06   1.12    1.04
             factor I                                                                               

  CRP        C−reactive\               12944    −1.33   −1.39   −1.01   −1.15\*     1.32    1.14    1.13
             protein                                                                                

  CTSC       cathepsin C               13032    −1.56   −2.52   1.01    −1.36       −1.96   1.04    −1.35

  F10        coagulation\              14058    −1.62   −1.42   −1.09   −1.13       −1.00   1.07    −1.07
             factor X                                                                               

  F11        coagulation\              109821   −2.17   −2.68   −1.41   −2.08\*\*   −1.08   −1.08   −1.34\*
             factor XI                                                                              

  F12        coagulation\              58992    −1.22   −1.35   −1.05   −1.14       −1.21   −1.07   −1.12\*
             factor XII                                                                             

  F13B       coagulation\              14060    −1.41   −1.54   −1.11   −1.22\*\*   1.02    1.02    −1.12
             factor XIII,\                                                                          
             B polypeptide                                                                          

  F2         coagulation\              14061    −1.19   −1.20   −1.02   −1.13\*     −1.10   1.02    −1.02
             factor II (thrombin)                                                                   

  F5         coagulation\              14067    −1.78   −1.53   −1.09   −1.44\*     −1.41   1.08    −1.34\*
             factor V                                                                               

  F7         coagulation\              14068    −2.68   −2.15   −1.09   −1.46\*\*   −1.23   1.03    −1.03
             factor VII                                                                             

  F9         coagulation\              14071    −1.42   −1.43   −1.02   −1.39\*     −1.33   1.07    −1.19
             factor IX                                                                              

  FGA        fibrinogen\               14161    −1.27   −1.75   1.00    −1.12       −1.07   1.05    −1.07
             alpha chain                                                                            

  FGB        fibrinogen\               110135   −1.32   −1.97   1.03    −1.15       −1.25   1.08    −1.07
             beta chain                                                                             

  FGG        fibrinogen gamma\         99571    −1.14   −1.68   1.02    −1.15\*     −1.08   1.04    −1.06
             chain                                                                                  

  KLKB1      kallikrein B,\            16621    −1.58   −1.76   −1.09   −1.39\*     −1.05   −1.03   −1.18\*
             plasma (Fletcher\                                                                      
             factor) 1                                                                              

  LUM        lumican                   17022    −1.34   −1.27   1.02    −1.20\*     −1.66   1.03    −1.27

  MASP1      Mannan-\                  17174    −1.23   −1.62   −1.19   −1.18\*     1.11    1.18    1.17\*
             binding lectin1                                                                        

  MBL2       Mannose-binding\          17195    −1.77   −2.18   −1.12   −1.23\*     −1.36   −1.20   −1.28\*\*
             lectin 2                                                                               

  ORM2       orosomucoid 2             18405    −1.96   −2.04   −1.26   −1.21       −1.16   1.30    1.05

  PROC       protein C                 19123    −1.49   −1.50   −1.02   −1.13\*     −1.09   −1.01   −1.09\*

  SAA1       serum amyloid\            20209    −3.71   −3.98   −2.75   1.04        −2.76   6.51    2.55
             A1                                                                                     

  SAA2       serum amyloid\            20210    −1.75   −1.30   −1.79   −1.29       3.05    1.44    1.22
             A2                                                                                     

  SAA4       serum amyloid\            20211    −2.19   −1.45   −1.06   −1.27       −1.02   1.47    −1.05
             A4, constitutive                                                                       

  SERPINA1   serpin peptidase\         20701    −3.43   −2.07   −1.03   −1.05\*\*   −1.16   1.11    −1.33
             inhibitor, clade A1                                                                    

  SERPINC1   serpin peptidase\         11905    −1.19   −1.21   −1.03   −1.08\*     −1.02   −1.04   −1.06\*
             inhibitor, clade C1                                                                    

  SERPIND1   serpin peptidase\         15160    −1.62   −1.70   −1.08   −1.25\*\*   −1.05   1.09    1.05
             inhibitor, clade D1                                                                    

  SERPINE1   serpin peptidase\         18787    1.44    9.75    1.03    1.85\*\*    2.95    1.03    1.26\*
             inhibitor, clade E1                                                                    

  SERPINF2   serpin peptidase\         18816    −1.15   −1.87   1.01    −1.13\*     1.02    1.12    1.05
             inhibitor, clade F2                                                                    

  SERPING1   serpin peptidase\         12258    −1.23   −1.37   −1.12   −1.13       −1.07   1.12    1.02
             inhibitor, clade G1                                                                    

  VWF        von Willebrand\           22371    1.06    1.12    −1.25   1.07        −1.51   1.22    1.14
             factor                                                                                 
  -------------------------------------------------------------------------------------------------------------

^1^From Rosen et al. \[[@B34]\],

\*Significantly different than control (*P* ≤ .03),

\*\*Significantly different than control (*P* ≤ .0025).

###### 

Average fold change for genes related to xenobiotic metabolism in wild-type and PPAR*α*-null male mice following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS.

  ------------------------------------------------------------------------------------------------------------------
                                                                     WT                          Null    
  ---------- ------------------------------ -------- ------- ------- ------- ---------- -------- ------- -----------
  ADH1C      alcohol dehydrogenase 1C       11522    1.27    1.02    −1.00   1.02       −1.09    −1.02   −1.04

  ADH5       alcohol dehydrogenase 5        11532    −1.18   1.10    1.09    −1.04      −1.02    1.11    1.14

  ADH7       alcohol dehydrogenase 7        11529    −1.51   1.06    −1.01   −1.06      −1.71    −1.01   −1.01

  ALDH1L1    aldehyde dehydrogenase 1L1     107747   −1.29   −1.85   −1.08   −1.18\*    −1.41    1.76    1.68\*\*

  ALDH3B1    aldehyde dehydrogenase\        67689    1.12    1.04    −1.11   1.04       1.48     −1.03   −1.11
             3B1                                                                                         

  CES1       carboxylesterase 1             12623    1.43    2.29    1.61    2.62\*\*   3.15     4.80    4.84\*\*

  CES2       carboxylesterase 2             234671   3.37    5.75    1.03    2.29       4.25     1.41    1.74\*

  CYP1A1     cytochrome\                    13076    1.25    −1.93   −1.05   1.08       −1.02    1.34    1.49\*\*
             P450,1A1                                                                                    

  CYP1A2     cytochrome\                    13077    −1.67   −1.24   −1.13   1.10       1.26     1.15    1.25\*
             P450,1A2                                                                                    

  CYP2A4     cytochrome\                    13087    −4.26   1.33    1.08    2.01       5.82     1.28    1.57\*\*
             P450,2A4                                                                                    

  CYP2B10    cytochrome\                    13088    1.31    4.39    3.50    5.92\*     24.20    11.34   21.66\*\*
             P450,2B10                                                                                   

  CYP2C55    cytochrome\                    72082    1.58    21.72   1.54    8.37\*     110.35   10.57   25.18\*\*
             P450,2C55                                                                                   

  CYP2C37    cytochrome\                    13096    −2.42   1.57    1.39    1.48       4.09     1.53    1.68
             P450,2C37                                                                                   

  CYP2C38    cytochrome\                    13097    1.62    1.12    1.78    2.30\*\*   −1.42    −1.26   1.03
             P450, 2C38                                                                                  

  CYP2C39    cytochrome\                    13098    2.45    1.51    1.65    1.51       −1.42    1.11    −1.01
             P450, 2C39                                                                                  

  CYP2C50    cytochrome\                    107141   −2.63   1.31    1.11    1.19       1.71     1.34    1.26
             P450,2C50                                                                                   

  CYP2C54    cytochrome\                    404195   −2.98   1.44    1.16    1.14       1.87     1.29    1.35\*\*
             P450,2C54                                                                                   

  CYP2C70    cytochrome\                    226105   −2.75   −4.22   −1.23   −1.68\*    −1.05    −1.05   1.04
             P450,2C70                                                                                   

  CYP2C65    cytochrome\                    72303    1.44    1.63    −1.93   1.98       46.78    2.28    8.63\*\*
             P450,2C65                                                                                   

  CYP2D10    cytochrome\                    13101    −1.47   −1.09   −1.02   −1.03      1.33     −1.00   1.02
             P450,2D10                                                                                   

  CYP2D26    cytochrome\                    76279    −1.17   −1.21   1.06    −1.01      −1.12    −1.03   −1.08
             P450,2D26                                                                                   

  CYP3A11    cytochrome\                    13112    −1.23   1.40    1.03    1.06       4.61     1.12    1.20
             P450,3A11                                                                                   

  CYP3A41A   cytochrome\                    53973    −2.08   1.11    1.24    1.58\*     2.01     1.39    1.25
             P450,3A41A                                                                                  

  CYP3A25    cytochrome\                    56388    −1.94   −1.70   1.01    −1.01      1.04     1.13    1.12
             P450,3A25                                                                                   

  CYP3A13    cytochrome\                    13113    −1.54   1.19    1.22    1.38\*     1.52     1.75    1.62\*\*
             P450,3A13                                                                                   

  EPHX1      epoxide hydrolase 1,\          13849    1.22    1.78    1.16    1.60\*     1.82     1.33    1.59\*
             microsomal                                                                                  

  EPHX2      epoxide hydrolase 2,\          13850    2.25    2.34    1.45    1.67\*\*   1.04     1.05    1.07
             cytoplasmic                                                                                 

  GSTA3      glutathione\                   14859    1.08    −1.04   1.05    1.26       1.11     1.11    1.13
             S-transferase A3                                                                            

  GSTA4      glutathione\                   14860    −2.01   −1.10   −1.02   1.52       1.37     −1.20   1.36
             S-transferase A4                                                                            

  GSTA5      glutathione\                   14857    −1.12   1.44    1.19    2.76\*     2.26     1.15    2.13
             S-transferase A5                                                                            

  GSTK1      glutathione\                   76263    1.85    1.43    1.02    −1.04      −1.30    −1.26   −1.27
             S-transferase kappa 1                                                                       

  GSTM1      glutathione\                   14863    −2.12   −1.56   −1.51   1.77       2.54     1.18    1.97
             S-transferase M1                                                                            

  GSTM3      glutathione\                   14864    −1.32   1.50    1.16    2.44\*     1.83     1.57    2.59\*
             S-transferase, mu 3                                                                         

  GSTM4      glutathione\                   14865    2.07    3.13    1.30    2.40\*     2.48     1.40    2.63\*
             S-transferase M4                                                                            

  GSTP1      glutathione\                   14870    −2.79   4.14    −1.16   1.00       2.87     −1.06   −1.03
             S-transferase pi 1                                                                          

  GSTT2      glutathione\                   14872    1.64    2.74    1.42    1.83\*\*   1.13     1.16    1.43\*\*
             S-transferase theta 2                                                                       

  GSTT3      glutathione\                   103140   2.10    1.13    1.41    1.61       1.77     1.30    1.85\*\*
             S-transferase, theta 3                                                                      

  GSTZ1      glutathione\                   14874    −1.36   −1.14   −1.03   −1.08      1.01     1.03    1.01
             transferase zeta 1                                                                          

  MGST1      microsomal\                    56615    1.28    1.24    −1.02   1.01       1.21     1.04    1.01
             glutathione S-transferase 1                                                                 

  MGST3      microsomal\                    66447    1.73    1.60    1.24    1.80\*     −1.54    −1.31   −1.06
             glutathione S-transferase 3                                                                 

  POR        P450 (cytochrome)\             18984    −1.26   2.63    1.27    1.94       2.04     2.91    3.30\*\*
             oxidoreductase                                                                              

  UGT2B17    UDP glucuronosyltransferase\   71773    −3.90   −1.13   −1.03   1.02       1.24     1.03    −1.01
             2B17                                                                                        

  UGT2B4     UDP glucuronosyltransferase\   552899   −1.37   −1.93   −1.26   −1.23\*    1.35     1.01    1.03
             2B4                                                                                         

  UGT2B7     UDP glucuronosyltransferase\   231396   −1.19   −1.20   −1.05   −1.05      1.16     1.04    −1.00
             2B7                                                                                         
  ------------------------------------------------------------------------------------------------------------------

^1^From Rosen et al. (2008),

\*Significantly different than control (*P* ≤ .03),

\*\*Significantly different than control (*P* ≤ .0025).

###### 

Average fold change for genes related to cholesterol biosynthesis in wild-type and PPAR*α*-null male mice following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS.

  -----------------------------------------------------------------------------------------------------------
                                                                 WT                        Null    
  -------- ----------------------------- -------- ------ ------- ------ ---------- ------- ------- ----------
  CYP51    cytochrome P450,\             13121    2.85   1.37    1.27   2.10\*     1.37    2.99    1.93\*\*
           family 51                                                                               

  FDFT1    farnesyl-diphosphate\         14137    2.30   1.28    1.29   1.73\*     1.09    2.00    1.92\*\*
           farnesyltransferase 1                                                                   

  FDPS     farnesyl diphosphate\         110196   3.19   1.79    1.16   1.38       1.83    1.84    1.96\*\*
           synthase                                                                                

  HMGCR    3-hydroxy-3-methylglutaryl\   15357    1.79   −1.08   1.19   1.97\*\*   1.20    1.85    1.80\*
           -CoA reductase                                                                          

  HMGCS1   3-hydroxy-3-methylglutaryl\   208715   6.67   1.79    1.15   1.61       −1.06   3.11    1.86\*
           -CoA synthase 1                                                                         

  HMGCS2   3-hydroxy-3-methylglutaryl\   15360    1.17   1.54    1.28   1.34\*     1.25    −1.08   −1.28\*
           -CoA synthase 2                                                                         

  IDI1     isopentenyl-diphosphate\      319554   3.14   1.61    1.35   1.62       1.40    1.96    1.57\*
           delta isomerase 1                                                                       

  LSS      lanosterol synthase           16987    1.73   1.08    1.12   1.41       −1.26   1.98    2.13\*\*

  MVK      mevalonate kinase             17855    1.45   −1.24   1.12   1.22       −1.02   1.57    1.52\*\*

  PMVK     phosphomevalonate kinase      68603    3.23   2.04    1.36   1.51\*     1.20    1.58    1.53\*\*

  SQLE     squalene epoxidase            20775    3.10   1.05    1.17   1.46       1.26    2.25    1.98\*\*
  -----------------------------------------------------------------------------------------------------------

^1^From Rosen et al. (2008), \*Significantly different than control (*P* ≤ .03),

\*\*Significantly different than control (*P* ≤ .0025).

###### 

Average fold change for genes related to oxidative phosphorylation/electron transport in wild-type and PPAR*α*-null male mice following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS.

  ------------------------------------------------------------------------------------------------------------------
                                                                       WT                        Null    
  ---------- -------------------------------- -------- ------- ------- ------- --------- ------- ------- -----------
  ATP5D      ATP synthase H+\                 66043    1.03    1.10    1.04    1.09      −1.17   −1.22   −1.13\*
             transporting,\                                                                              
             F1delta                                                                                     

  ATP5E      ATP synthase H+\                 67126    −1.10   1.21    −1.00   1.03      −1.17   −1.32   −1.38\*\*
             transporting,\                                                                              
             F1epsilon                                                                                   

  ATP5G2     ATP synthase H+\                 67942    −1.09   −1.03   1.10    −1.10     −1.10   −1.33   −1.26\*\*
             transporting,\                                                                              
             F0, C2                                                                                      

  ATP5G3     ATP synthase H+\                 228033   1.62    1.48    −1.01   1.05      −1.10   −1.12   −1.10\*\*
             transporting,\                                                                              
             F0, C3                                                                                      

  ATP5H      ATP synthase H+\                 71679    1.18    1.10    1.05    1.06      −1.01   −1.30   −1.38\*\*
             transporting,\                                                                              
             F0, D                                                                                       

  ATP5I      ATP synthase H+\                 11958    −1.01   −1.45   −1.03   1.10      1.17    −1.38   −1.50\*\*
             transporting,\                                                                              
             F0, E                                                                                       

  ATP5J      ATP synthase H+\                 11957    −1.20   1.44    −1.04   −1.07     −1.14   −1.25   −1.35\*\*
             transporting,\                                                                              
             F0, F6                                                                                      

  ATP5J2     ATP synthase H+\                 57423    2.38    −1.56   −1.05   −1.09     1.03    −1.29   −1.35\*\*
             transporting,F0, F2                                                                         

  ATP5L      ATP synthase H+ transporting,\   27425    1.58    1.21    −1.02   1.00      −1.05   −1.33   −1.30\*\*
             F0, G                                                                                       

  ATP5O      ATP synthase H+\                 28080    1.12    1.16    1.06    1.22      −1.03   −1.33   −1.31\*\*
             transporting,\                                                                              
             F1, O                                                                                       

  ATP6V0B    ATPase, H+\                      114143   −1.37   −1.25   1.03    −1.09     1.05    −1.22   −1.20\*\*
             transporting,\                                                                              
             V0 unit b                                                                                   

  ATP6V1F    ATPase, H+\                      66144    −1.18   1.23    1.00    1.05      1.01    −1.33   −1.28\*\*
             transporting,\                                                                              
             V1 unit F                                                                                   

  COX4I1     cytochrome c\                    12857    1.14    1.15    1.02    1.03      −1.15   −1.19   −1.16\*\*
             oxidase unit\                                                                               
             IV isoform 1                                                                                

  COX5A      cytochrome c\                    12858    1.25    1.12    −1.02   1.09      −1.13   −1.26   −1.33\*\*
             oxidase unit Va                                                                             

  COX5B      cytochrome c\                    12859    1.19    1.33    1.09    1.08      −1.27   −1.27   −1.35\*\*
             oxidase unit Vb                                                                             

  COX6B1     cytochrome c\                    110323   1.32    1.39    −1.01   1.10\*    −1.12   −1.25   −1.19\*
             oxidase unit VIb1                                                                           

  COX6C      cytochrome c\                    12864    1.62    −1.23   1.03    −1.05     1.21    −1.22   −1.25\*\*
             oxidase unit VIc                                                                            

  COX7A2     cytochrome c\                    12866    −1.68   −1.08   −1.04   −1.04     −1.57   −1.39   −1.37\*\*
             oxidase unit VIIa 2                                                                         

  COX7C      cytochrome c\                    12867    1.22    1.32    −1.03   −1.28\*   −1.05   −1.23   −1.19\*\*
             oxidase unit VIIc                                                                           

  COX8A      cytochrome c\                    12868    1.34    1.34    1.02    1.04      1.07    −1.23   −1.13\*
             oxidase unit 8A                                                                             

  NDUFA1     NADH dehydrogenase 1\            54405    −1.19   1.13    −1.03   −1.11     −1.25   −1.31   −1.49\*\*
             alpha1                                                                                      

  NDUFA2     NADH dehydrogenase 1\            17991    1.06    1.18    1.04    1.04      −1.06   −1.26   −1.33\*\*
             alpha 2                                                                                     

  NDUFA3     NADH dehydrogenase 1\            66091    1.60    1.60    1.06    1.16\*    −1.06   −1.37   −1.30\*\*
             alpha 3                                                                                     

  NDUFA4     NADH dehydrogenase 1\            17992    1.02    2.46    −1.00   1.01      3.16    −1.12   −1.11\*\*
             alpha 4                                                                                     

  NDUFA5     NADH dehydrogenase 1\            68202    1.41    1.26    1.10    1.11      −1.07   −1.55   −1.73\*\*
             alpha 5                                                                                     

  NDUFA6     NADH dehydrogenase 1\            67130    1.10    1.06    1.02    −1.04     −1.02   −1.34   −1.29\*\*
             alpha 6                                                                                     

  NDUFA7     NADH dehydrogenase 1\            66416    −1.14   −1.01   1.09    1.12      −1.17   −1.45   −1.38\*\*
             alpha 7                                                                                     

  NDUFA8     NADH dehydrogenase 1\            68375    1.14    1.33    1.00    1.09      1.05    −1.29   −1.18\*
             alpha 8                                                                                     

  NDUFA12    NADH dehydrogenase 1\            66414    1.47    1.16    −1.03   1.06      1.06    −1.51   −1.40\*\*
             alpha12                                                                                     

  NDUFA13    NADH dehydrogenase 1\            67184    −1.12   −1.16   −1.03   −1.03     −1.08   −1.26   −1.28\*\*
             alpha13                                                                                     

  NDUFA9     NADH dehydrogenase 1\            66108    1.18    1.07    1.02    −1.01     −1.09   −1.20   −1.19\*\*
             alpha 9                                                                                     

  NDUFAB1    NADH dehydrogenase 1,\           70316    1.56    1.19    1.05    1.23\*    −1.07   −1.31   −1.44\*
             alpha/beta 1                                                                                

  NDUFB2     NADH dehydrogenase 1\            68198    −2.31   −3.32   1.04    1.11      1.49    −1.31   −1.35\*\*
             beta 2                                                                                      

  NDUFB3     NADH dehydrogenase 1\            66495    1.55    1.93    1.09    1.19      1.05    −1.41   −1.32\*\*
             beta 3                                                                                      

  NDUFB4     NADH dehydrogenase 1\            68194    −1.03   1.17    −1.01   1.06      −1.13   −1.45   −1.46\*\*
             beta 4                                                                                      

  NDUFB5     NADH dehydrogenase 1\            66046    1.21    1.13    1.08    1.03      1.05    −1.28   −1.41\*\*
             beta 5                                                                                      

  NDUFB6     NADH dehydrogenase 1\            230075   1.32    −1.03   1.04    1.19      −1.02   −1.38   −1.36\*\*
             beta 6,                                                                                     

  NDUFB7     NADH dehydrogenase 1\            66916    1.02    1.14    1.04    1.11      −1.11   −1.40   −1.29\*\*
             beta 7,                                                                                     

  NDUFB9     NADH dehydrogenase 1\            66218    1.19    1.01    1.05    1.01      −1.08   −1.22   −1.25\*\*
             beta 9,                                                                                     

  NDUFB11    NADH dehydrogenase 1\            104130   −1.29   1.05    1.05    1.06      −1.00   −1.26   −1.23\*\*
             beta 11                                                                                     

  NDUFC1     NADH dehydrogenase 1\            66377    −1.28   1.84    1.07    1.21\*    1.17    −1.28   −1.37\*\*
             unknown 1                                                                                   

  NDUFC2     NADH dehydrogenase 1\            68197    −1.02   1.13    1.06    1.06      −1.13   −1.37   −1.33\*\*
             unknown, 2                                                                                  

  NDUFS4     NADH dehydrogenase\              17993    1.51    1.21    1.12    −1.12     1.07    −1.41   −1.40\*\*
             Fe-S protein 4                                                                              

  NDUFS5     NADH dehydrogenase\              595136   1.16    1.13    −1.01   1.08      1.02    −1.37   −1.44\*\*
             Fe-S protein 5                                                                              

  NDUFS7     NADH dehydrogenase\              75406    1.09    1.40    1.09    1.13\*    1.07    −1.28   −1.15
             Fe-S protein 7                                                                              

  NDUFS6     NADH dehydrogenase\              407785   −1.32   1.06    −1.01   1.02      −1.14   −1.30   −1.32\*\*
             Fe-S protein 6                                                                              

  NDUFV2     NADH dehydrogenase\              72900    1.38    1.09    1.06    1.07      −1.02   −1.24   −1.24\*\*
             flavoprotein 2                                                                              

  NDUFV3     NADH dehydrogenase\              78330    1.12    1.16    −1.03   −1.01     −1.14   −1.35   −1.39\*\*
             flavoprotein 3,                                                                             

  UCRC       ubiquinol-cytochrome c\          66152    1.58    1.26    1.10    1.27      1.07    −1.40   −1.27\*\*
             reductase                                                                                   

  UHRF1BP1   UHRF1 binding\                   224648   −1.03   1.36    −1.08   1.06      1.15    1.23    1.15\*\*
             protein 1                                                                                   

  UQCR       ubiquinol-cytochrome\            66594    1.26    1.40    1.04    1.14\*    1.09    −1.28   −1.19\*
             c reductase                                                                                 

  UQCRC2     ubiquinol-cytochrome\            67003    1.09    1.17    1.07    1.13      −1.04   −1.11   −1.27\*
             c reductase CP II                                                                           

  UQCRQ      ubiquinol-cytochrome\            22272    1.01    1.08    1.07    1.12\*    −1.07   −1.18   −1.21\*\*
             c reductase 3 unit 7                                                                        
  ------------------------------------------------------------------------------------------------------------------

^1^From Rosen et al. \[[@B34]\], \*Significantly different than control (*P* ≤ .03),\*\*Significantly different than control (*P* ≤ .0025).

###### 

Average fold change for genes related to ribosome biogenesis following a seven-day exposure to Wy-14,643^1^, PFOA^1^, or PFOS in wild-type and PPAR*α*-null male mice.

  ----------------------------------------------------------------------------------------------------------
                                                              WT                         Null    
  --------- ------------------------ -------- ------- ------- ------- ---------- ------- ------- -----------
  MRPL12    mitochondrial\           56282    −1.16   1.25    1.07    1.14\*     −1.16   −1.18   −1.12\*
            ribosomal protein L12                                                                

  MRPL13    mitochondrial\           68537    1.32    1.33    1.12    1.35\*     1.01    −1.21   −1.42\*\*
            ribosomal protein L13                                                                

  MRPL17    mitochondrial\           27397    1.68    1.76    1.10    1.43\*\*   1.13    −1.13   1.09
            ribosomal protein L17                                                                

  MRPL23    mitochondrial\           19935    −1.14   −1.04   −1.00   1.10       1.09    −1.38   −1.20\*
            ribosomal protein L23                                                                

  MRPL33    mitochondrial\           66845    1.22    1.26    1.07    1.05       1.04    −1.29   −1.28\*\*
            ribosomal protein L33                                                                

  MRPS12    mitochondrial\           24030    −1.24   1.18    1.05    1.12       1.02    −1.27   −1.15
            ribosomal protein S12                                                                

  MRPS18A   mitochondrial\           68565    −1.46   1.34    1.04    1.28\*     1.60    −1.19   −1.06
            ribosomal protein S18A                                                               

  RPL10     ribosomal protein\       110954   −1.15   −1.21   1.02    1.03       1.07    −1.10   −1.02
            L10                                                                                  

  RPL10A    ribosomal protein\       19896    −1.11   1.10    1.03    1.05       1.00    −1.07   1.01
            L10A                                                                                 

  RPL11     ribosomal protein\       67025    1.14    1.12    1.10    1.11\*     1.15    −1.15   −1.09
            L11                                                                                  

  RPL12     ribosomal protein\       269261   1.01    1.37    1.08    1.15\*     1.11    −1.08   1.05
            L12                                                                                  

  RPL13A    ribosomal protein\       22121    −1.14   1.03    1.07    1.12\*     −1.17   −1.15   −1.10
            L13a                                                                                 

  RPL14     ribosomal protein\       67115    −1.28   −1.06   1.15    1.23\*\*   −1.13   −1.18   −1.22\*
            L14                                                                                  

  RPL17     ribosomal protein\       319195   −1.27   1.15    1.03    1.12       −1.52   −1.10   −1.09
            L17                                                                                  

  RPL18     ribosomal protein\       19899    −1.11   1.28    1.04    1.07\*     1.19    −1.27   −1.09\*
            L18                                                                                  

  RPL18A    ribosomal protein\       76808    1.65    −1.37   1.04    1.11\*     1.08    −1.15   −1.02
            L18a                                                                                 

  RPL19     ribosomal protein\       19921    1.22    1.23    1.01    1.05       1.07    −1.11   −1.03
            L19                                                                                  

  RPL21     ribosomal protein\       19933    2.00    1.55    1.03    1.09       1.18    −1.20   −1.18
            L21                                                                                  

  RPL22     ribosomal protein\       19934    1.17    1.45    1.06    1.29\*\*   1.08    −1.25   −1.14\*
            L22                                                                                  

  RPL23     ribosomal protein\       65019    −1.07   1.35    1.06    1.06       1.22    −1.24   −1.16
            L23                                                                                  

  RPL24     ribosomal protein\       68193    −1.13   1.07    1.06    1.09\*     −1.00   −1.19   −1.11\*
            L24                                                                                  

  RPL26     ribosomal protein\       19941    1.04    1.22    1.03    1.03       1.07    −1.22   −1.18\*\*
            L26                                                                                  

  RPL27     ribosomal protein\       19942    1.04    −1.01   1.08    1.38\*\*   1.06    −1.25   −1.40\*
            L27                                                                                  

  RPL27A    ribosomal protein\       26451    −1.07   1.07    −1.00   1.17       1.26    −1.17   −1.09
            L27a                                                                                 

  RPL28     ribosomal protein\       19943    1.29    1.04    1.01    1.11\*     1.67    −1.22   −1.10
            L28                                                                                  

  RPL29     ribosomal protein\       19944    1.16    −1.30   1.04    1.09       1.08    −1.23   −1.17
            L29                                                                                  

  RPL3      ribosomal protein\       27367    −1.00   −1.14   1.01    1.09       −1.01   −1.03   1.06
            L3                                                                                   

  RPL30     ribosomal protein\       19946    −1.15   −1.07   1.02    −1.21      −1.04   −1.29   −1.23\*\*
            L30                                                                                  

  RPL31     ribosomal protein\       114641   1.11    1.37    1.09    1.05       1.29    −1.18   −1.12\*
            L31                                                                                  

  RPL32     ribosomal protein\       19951    1.06    1.11    1.02    1.12\*     1.08    −1.16   −1.03
            L32                                                                                  

  RPL34     ribosomal protein\       68436    −1.26   1.16    −1.07   1.05       −1.04   −1.22   −1.31\*\*
            L34                                                                                  

  RPL35     ribosomal protein\       66489    −1.03   1.15    1.13    1.26\*\*   1.04    −1.17   −1.11
            L35                                                                                  

  RPL36     ribosomal protein\       54217    −1.07   1.12    1.09    1.23\*     1.07    −1.27   −1.20\*
            L36                                                                                  

  RPL37     ribosomal protein\       67281    −1.16   −1.18   1.04    1.27\*     1.17    −1.19   −1.10\*\*
            L37                                                                                  

  RPL37A    ribosomal protein\       19981    −1.15   −1.09   1.03    1.16       −1.12   −1.22   −1.19\*
            L37a                                                                                 

  RPL38     ribosomal protein\       67671    −1.17   1.14    −1.01   1.06       −1.03   −1.18   −1.10
            L38                                                                                  

  RPL39     ribosomal protein\       67248    1.04    1.02    1.06    1.13\*     1.07    −1.18   −1.16\*\*
            L39                                                                                  

  RPL4      ribosomal protein\       67891    1.16    1.43    1.03    1.03       1.32    1.03    1.04
            L4                                                                                   

  RPL41     ribosomal protein\       67945    −1.06   1.14    1.05    1.06       −1.13   −1.20   −1.26\*
            L41                                                                                  

  RPL5      ribosomal protein\       19983    −1.21   1.02    1.24    1.09\*     −1.05   −1.05   −1.11
            L5                                                                                   

  RPL6      ribosomal protein\       19988    1.01    −1.08   1.00    1.05       1.15    −1.05   1.03
            L6                                                                                   

  RPL7A     ribosomal protein\       27176    −1.02   −1.11   1.01    1.01       −1.02   −1.07   1.01
            L7a                                                                                  

  RPL9      ribosomal protein\       20005    −1.35   −1.08   1.03    1.07       −1.11   −1.19   −1.12\*
            L9                                                                                   

  RPS10     ribosomal protein\       67097    −1.02   1.02    1.05    1.07       1.00    −1.17   −1.12\*
            S10                                                                                  

  RPS11     ribosomal protein\       27207    1.05    −1.74   −1.01   1.11       1.06    −1.24   −1.14\*
            S11                                                                                  

  RPS12     ribosomal protein\       20042    1.16    1.22    1.11    1.19       1.22    −1.21   −1.12
            S12                                                                                  

  RPS13     ribosomal protein\       68052    −1.03   1.10    1.07    1.22\*     1.11    −1.27   −1.22\*
            S13                                                                                  

  RPS14     ribosomal protein\       20044    −1.03   1.19    1.05    1.11\*     1.01    −1.17   −1.11\*\*
            S14                                                                                  

  RPS15A    ribosomal protein\       267019   −1.05   1.05    1.02    1.12       1.02    −1.14   −1.20
            S15a                                                                                 

  RPS16     ribosomal protein\       20055    −1.09   1.05    1.05    1.07       −1.02   −1.12   −1.07
            S16                                                                                  

  RPS17     ribosomal protein\       20068    1.00    1.16    1.04    −1.19\*    1.01    −1.19   −1.15\*
            S17                                                                                  

  RPS19     ribosomal protein\       20085    −1.07   1.23    1.08    1.19\*\*   −1.00   −1.14   −1.05
            S19                                                                                  

  RPS2      ribosomal protein\       16898    −1.09   1.02    1.04    1.02       −1.16   −1.03   1.04
            S2                                                                                   

  RPS20     ribosomal protein\       67427    −1.40   1.21    1.04    1.15       1.25    −1.11   −1.13
            S20                                                                                  

  RPS21     ribosomal protein\       66481    1.11    −1.32   1.15    1.38       1.39    −1.32   −1.25\*\*
            S21                                                                                  

  RPS23     ribosomal protein\       66475    1.01    1.04    −1.00   1.04       1.09    −1.21   −1.10\*
            S23                                                                                  

  RPS24     ribosomal protein\       20088    1.58    1.62    1.11    −1.29\*    1.75    −1.16   −1.19\*\*
            S24                                                                                  

  RPS25     ribosomal protein\       75617    −1.23   1.01    1.09    1.13\*     −1.02   −1.30   −1.17\*
            S25                                                                                  

  RPS26     ribosomal protein\       27370    1.32    1.30    1.04    1.16\*     1.14    −1.20   −1.08
            S26                                                                                  

  RPS27A    ribosomal protein\       78294    1.05    −1.05   −1.00   1.02       1.09    −1.08   −1.05
            S27a                                                                                 

  RPS27L    ribosomal protein\       67941    1.72    1.28    1.07    1.14\*     1.19    −1.18   −1.17\*
            S27-like                                                                             

  RPS28     ribosomal protein\       54127    −1.19   −1.03   1.03    1.06       −1.05   −1.28   −1.17\*
            S28                                                                                  

  RPS29     ribosomal protein\       20090    −1.26   −1.05   −1.02   1.01       −1.03   −1.19   −1.20\*\*
            S29                                                                                  

  RPS3      ribosomal protein\       27050    −1.04   1.29    1.03    1.20\*     −2.88   −1.11   −1.06
            S3                                                                                   

  RPS3A     ribosomal protein\       544977   −1.18   −1.07   1.02    −1.01      −1.05   −1.10   −1.03
            S3A                                                                                  

  RPS5      ribosomal protein\       20103    −1.16   1.18    1.06    1.09\*     −1.02   −1.13   −1.00
            S5                                                                                   

  RPS6      ribosomal protein\       20104    −1.20   −1.02   −1.20   1.06       −1.02   −1.14   −1.06\*
            S6                                                                                   

  RPS8      ribosomal protein\       20116    1.19    −1.05   1.07    1.13\*     1.04    −1.29   −1.13
            S8                                                                                   

  RPS9      ribosomal protein\       76846    −1.39   1.30    1.05    1.07       1.05    −1.08   −1.04
            S9                                                                                   
  ----------------------------------------------------------------------------------------------------------

^1^From Rosen et al. (2008), \*Significantly different than control (*P* ≤ .03),

\*\*Significantly different from control (*P* ≤ .0025).

[^1]: Academic Editor: Michael Cunningham
